Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?

被引:208
|
作者
Lazzarini, L [1 ]
Lipsky, BA
Mader, JT
机构
[1] S Bortolo Hosp, Dept Infect Dis & Trop Med, I-36100 Vicenza, Italy
[2] VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA
[3] VA Puget Sound Hlth Care Syst, Antibiot Res Clin, Seattle, WA USA
[4] Univ Washington, Dept Med, Seattle, WA USA
[5] Univ Texas, Med Branch, Galveston, TX USA
关键词
osteomyelitis; infection; bone; antibiotic; therapy; treatment;
D O I
10.1016/j.ijid.2004.09.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives and design: To determine the most appropriate approach to antibiotic therapy for osteomyelitis, the medical literature for articles published from 1968 to 2000 was reviewed. Results: Ninety-three clinical trials in children and adults were identified using almost every antibiotic class. Most studies were non-comparative and the comparative trials involved relatively few patients. Publications generally did not provide clinically important information regarding infection staging or classification, surgical treatment provided, or the presence of orthopedic hardware. The median duration of follow-up after treatment was only 12 months. The clinical outcome was better for acute than chronic osteomyelitis in eight of the 12 studies allowing comparison. In the comparative trials, few statistically significant differences were observed between the tested treatments. In one small trial, the combination of nafcillin plus rifampin was more effective than nafcillin alone. In pediatric osteomyelitis, oral therapy with cloxacillin was more effective than tetracycline in one study, and oral clindamycin was as effective as parenteral. antistaphylococcal penicillins in another. In several investigations oral. fluoroquinolones were as effective as standard parenteral treatments. Conclusions: Although the optimal duration of antibiotic therapy remains undefined, most investigators treated patients for about six weeks. Despite three decades of research, the available Literature on the treatment of osteomyelitis is inadequate to determine the best agent(s), route, or duration of antibiotic therapy. (c) 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:127 / 138
页数:12
相关论文
共 50 条
  • [31] CCR1 Antagonists: What Have We Learned From Clinical Trials
    Gladue, Ronald P.
    Brown, Matthew F.
    Zwillich, Samuel H.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (13) : 1268 - 1277
  • [32] Testosterone Therapy: What We Have Learned From Trials
    Corona, Giovanni
    Torres, Luiz Otavio
    Maggi, Mario
    JOURNAL OF SEXUAL MEDICINE, 2020, 17 (03): : 447 - 460
  • [33] Antibiotic Treatment for Inpatient Asthma Exacerbations What Have We Learned?
    Newman, Thomas B.
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 427 - 428
  • [34] What have we learned from cardiac resynchronization trials?
    Zanon, F
    Baracca, E
    Bilato, C
    Aggio, S
    Zonzin, P
    NEW ADVANCES IN HEART FAILURE AND ATRIAL FIBRILLATION, 2003, : 391 - 394
  • [35] What have we learned from recent antiplatelet trials?
    Easton, JD
    NEUROLOGY, 1998, 51 (03) : S36 - S38
  • [36] What have we learned from recent dyspepsia trials?
    Ofman J.J.
    Current Gastroenterology Reports, 2000, 2 (6) : 471 - 477
  • [37] Stroke trials: What have we learned?
    Madhavan, R
    Jacobs, BS
    Levine, SR
    NEUROLOGICAL RESEARCH, 2002, 24 : S27 - S32
  • [38] 15 years of heart-failure trials: what have we learned?
    Massie, BM
    LANCET, 1998, 352 : 29 - 33
  • [39] Over 30 years of HABs in the Philippines and Malaysia: What have we learned?
    Yniguez, Aletta T.
    Lim, Po Teen
    Leaw, Chui Pin
    Jipanin, Steffiana J.
    Iwataki, Mitsunori
    Benico, Garry
    Azanza, Rhodora, V
    HARMFUL ALGAE, 2021, 102
  • [40] Dreissena in the Great Lakes: what have we learned in 30 years of invasion
    Karatayev, Alexander Y.
    Burlakova, Lyubov E.
    HYDROBIOLOGIA, 2022, 852 (5) : 1103 - 1130